Complete genome sequence of Streptomyces venezuelae ATCC 15439, a promising cell factory for production of secondary metabolites

Song, Ju Yeon; Yoo, Young Je; Lim, Seung Kwan; Ho, Sun; Kim, Ji Eun; Roe, Jung Hye; Kim, Jihyun F.; Yoon, Yeo Joon

doi:10.1016/j.jbiotec.2015.12.028

Cited by 19 publications

(13 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Meanwhile, the genomic studies of Streptomyces provide a basis for better understanding of the secondary metabolism and the production of target bioactive metabolites, thus creating an opportunity to obtain novel bioactive compounds 86,87 . With the availability of NGS technology, the whole genome of strain MUSC 1J T was subjected to sequencing.…”

Section: Discussionmentioning

confidence: 99%

Streptomyces monashensis sp. nov., a novel mangrove soil actinobacterium from East Malaysia with antioxidative potential

Law

Ser

Mutalib

et al. 2019

Sci Rep

View full text Add to dashboard Cite

A new Streptomyces species discovered from Sarawak mangrove soil is described, with the proposed name – Streptomyces monashensis sp. nov. (strain MUSC 1J T ). Taxonomy status of MUSC 1J T was determined via polyphasic approach. Phylogenetic and chemotaxonomic properties of strain MUSC 1J T were in accordance with those known for genus Streptomyces . Based on phylogenetic analyses, the strains closely related to MUSC 1J T were Streptomyces corchorusii DSM 40340 T (98.7%), Streptomyces olivaceoviridis NBRC 13066 T (98.7%), Streptomyces canarius NBRC 13431 T (98.6%) and Streptomyces coacervatus AS-0823 T (98.4%). Outcomes of DNA–DNA relatedness between strain MUSC 1J T and its closely related type strains covered from 19.7 ± 2.8% to 49.1 ± 4.3%. Strain MUSC 1J T has genome size of 10,254,857 bp with DNA G + C content of 71 mol%. MUSC 1J T extract exhibited strong antioxidative activity up to 83.80 ± 4.80% in the SOD assay, with significant cytotoxic effect against colon cancer cell lines HCT-116 and SW480. Streptomyces monashensis MUSC 1J T (=DSM 103626 T = MCCC 1K03219 T ) could potentially be a producer of novel bioactive metabolites; hence discovery of this new species may be highly significant to the biopharmaceutical industry as it could lead to development of new and useful chemo-preventive drugs.

show abstract

Section: Discussionmentioning

confidence: 99%

Streptomyces monashensis sp. nov., a novel mangrove soil actinobacterium from East Malaysia with antioxidative potential

Law

Ser

Mutalib

et al. 2019

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Subsequently, the information obtained from genomic analysis could improve the production of the target compound [150]. This can be achieved by several methods, for example, the overexpression of structural or regulatory genes involved in the biosynthesis of target metabolites, and the activation and expression of silent biosynthetic gene clusters in homologous or heterologous host.…”

Section: Limitations and Suggestions For Future Researchmentioning

confidence: 99%

Anticancer Drug Discovery from Microbial Sources: The Unique Mangrove Streptomycetes

Law

Letchumanan

et al. 2020

Molecules

View full text Add to dashboard Cite

Worldwide cancer incidence and mortality have always been a concern to the community. The cancer mortality rate has generally declined over the years; however, there is still an increased mortality rate in poorer countries that receives considerable attention from healthcare professionals. This suggested the importance of the prompt detection, effective treatment, and prevention strategies. The genus Streptomyces has been documented as a prolific producer of biologically active secondary metabolites. Streptomycetes from mangrove environments attract researchers’ attention due to their ability to synthesize diverse, interesting bioactive metabolites. The present review highlights research on mangrove-derived streptomycetes and the production of anticancer-related compounds from these microorganisms. Research studies conducted between 2008 and 2019, specifically mentioning the isolation of streptomycetes from mangrove areas and described the successful purification of compound(s) or generation of crude extracts with cytotoxic activity against human cancer cell lines, were compiled in this review. It is anticipated that there will be an increase in prospects for mangrove-derived streptomycetes as one of the natural resources for the isolation of chemotherapeutic agents.

show abstract

“…The genome of S. venezuleae ATCC 15439 has been sequenced recently by two independent groups (accession No. LN881739 and CP013129) revealing a genome of 9.03-9.05 Mb (Table 1) (He et al, 2016; Song et al, 2016). Three major mutants of S. venezuelae ATCC 15439 have been generated to better express foreign BGCs: DHS2001 which lacks all pik genes (Jung et al, 2006), YJ003 which lacks the des gene cluster (Hong et al, 2004), and YJ28 which lacks both pik and des genes (Jung et al, 2007).…”

Section: Streptomyces Venezuelae As a Heterologous Hostmentioning

confidence: 99%

Streptomycetes: Surrogate hosts for the genetic manipulation of biosynthetic gene clusters and production of natural products

Nepal

Wang

2019

Biotechnology Advances

View full text Add to dashboard Cite

Due to the worldwide prevalence of multidrug-resistant pathogens and high incidence of diseases such as cancer, there is an urgent need for the discovery and development of new drugs. Nearly half of the FDA-approved drugs are derived from natural products that are produced by living organisms, mainly bacteria, fungi, and plants. Commercial development is often limited by the low yield of the desired compounds expressed by the native producers. In addition, recent advances in whole genome sequencing and bioinformatics have revealed an abundance of cryptic biosynthetic gene clusters within microbial genomes. Genetic manipulation of clusters in the native host is commonly used to awaken poorly expressed or silent gene clusters, however, the lack of feasible genetic manipulation systems in many strains often hinders our ability to engineer the native producers. The transfer of gene clusters into heterologous hosts for expression of partial or entire biosynthetic pathways is an approach that can be used to overcome this limitation. Heterologous expression also facilitates the chimeric fusion of different biosynthetic pathways, leading to the generation of “unnatural” natural products. The genus Streptomyces is especially known to be a prolific source of drugs/antibiotics, its members are often used as heterologous expression hosts. In this review, we summarize recent applications of Streptomyces species, S. coelicolor, S. lividans, S. albus, S. venezuelae and S. avermitilis, as heterologous expression systems.

show abstract

Complete genome sequence of Streptomyces venezuelae ATCC 15439, a promising cell factory for production of secondary metabolites

Cited by 19 publications

References 11 publications

Streptomyces monashensis sp. nov., a novel mangrove soil actinobacterium from East Malaysia with antioxidative potential

Streptomyces monashensis sp. nov., a novel mangrove soil actinobacterium from East Malaysia with antioxidative potential

Anticancer Drug Discovery from Microbial Sources: The Unique Mangrove Streptomycetes

Streptomycetes: Surrogate hosts for the genetic manipulation of biosynthetic gene clusters and production of natural products

Contact Info

Product

Resources

About